Press Release


New DFG Priority Program "Ferroptosis: from basic research to clinical application"

"Ferroptosis: from basic research to clinical application" is one of the new priority programs that will be funded by the German Research Foundation (DFG) starting next year. Coordinator of the program is Dr. Marcus Conrad, Institute of Metabolism and Cell Death at Helmholtz Zentrum München.

In the new priority program, a group of about 20 researchers from all over Germany will gather to jointly address the promising potential of this emerging and rapidly expanding research field. Ferroptosis is a form of non-apoptotic cell death newly discovered a few years ago, which is involved in various diseases such as stroke, heart attack and neurodegeneration, and offers many starting points for pharmacological intervention. In addition, there is growing evidence that a number of hard-to-treat tumour types are highly susceptible to ferroptosis, which could lead to new clinical therapies.

"Ferroptose: From Basic Research to Clinical Application" is one of a total of 14 new collaborations selected by the DFG from 49 initiatives submitted for funding. The 14 new consortia will receive a total of approximately 85 million euros for an initial period of three years.